Zydus Mounts Challenge To Novartis With Generic Nelarabine Injection
US Rival To Arranon Has Been Granted 180 Days Of CGT Exclusivity
Zydus Cadila’s single-dose nelarabine injection (250mg/50ml) will enjoy 180 days of competitive generic therapy market exclusivity following approval from the US FDA, as the first approved rival to Novartis’ Arranon brand.
